Advanced search
Publication Cover
HIV Clinical Trials Volume 19, 2018 - Issue 4
Submit an article Journal homepage
4,379
Views
47
CrossRef citations to date
0
Altmetric
Original Articles

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

Miranda I. MurrayViiV Healthcare, London, UK; Correspondence[email protected]
View further author information
,
Martin MarkowitzThe Aaron Diamond AIDS Research Center, an affiliate of the Rockefeller University, New York, NY, USA; View further author information
,
Ian FrankPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; View further author information
,
Robert M. GrantInstitute of Virology and Immunology, Gladstone Institutes, San Francisco, CA, USA; ;Department of Medicine, University of California, San Francisco, CA, USA; View further author information
,
Kenneth H. MayerThe Fenway Institute, Fenway Health, Boston, MA, USA; ;Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; ORCID Iconhttp://orcid.org/0000-0001-7460-733XView further author information
ORCID Icon,
Krischan J. HudsonViiV Healthcare, Research Triangle Park, NC, USA; View further author information
,
Britt S. StancilPAREXEL International, Durham, NC, USA; View further author information
,
Susan L. FordGlaxoSmithKline, Research Triangle Park, NC, USAView further author information
,
Parul PatelViiV Healthcare, Research Triangle Park, NC, USA; View further author information
,
Alex R. RinehartViiV Healthcare, Research Triangle Park, NC, USA; View further author information
,
William R. SpreenViiV Healthcare, Research Triangle Park, NC, USA; View further author information
&
David A. MargolisViiV Healthcare, Research Triangle Park, NC, USA; View further author information
 show all
Pages 129-138 | Received 23 May 2018, Accepted 05 Aug 2018, Published online: 16 Nov 2018

References

  • WHO. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 2016 update. http://www.who.int/hiv/pub/guidelines/keypopulations-2016/en. Accessed March 12, 2018
  • Truvada [package insert]. Foster City, CA: Gilead Sciences; 2017.
  • Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
  • Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–2090.
  • Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434.
  • Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
  • McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.
  • Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–2246.
  • Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983.
  • Abdool Karim S, Baxter C. Translating pre-exposure prophylaxis evidence into practice and public health impact. In: Eaton LA, Kalichman SC, eds. Biomedical Advances in HIV Prevention: Social and Behavior Perspectives. New York: Springer; 2014:29–40.
  • Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481–486.
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
  • Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331–337.
  • Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422.
  • Markowitz M, Frank I, Grant RM, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e340.
  • Romaine J, Bradley C. The Study Medication Satisfaction Questionnaire (SMSQ) Status and Change Version User Guidelines. Egham, Surrey: Health Psycohology Research; 2015.
  • Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320–333.
  • Kerrigan D, Mantsios A, Grant R, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as PrEP in the context of a phase II trial in the United States. AIDS Behav. 2017. [Epub ahead of print].
  • Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518.
  • Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67(5):487–492.
  • Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–1399.
  • UNAIDS. Latest statistics on the status of the AIDS epidemic. http://www.unaids.org/en/resources/fact-sheet. Accessed May 20, 2018.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.